No Data
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor Conference
HC Wainwright & Co. Reiterates Buy on Equillium, Maintains $5 Price Target
Equillium Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Equillium (EQ), Foghorn Therapeutics (FHTX) and Immix Biopharma, Inc. (IMMX)
H.C. Wainwright Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $5
H.C. Wainwright analyst Ram Selvaraju maintains $Equillium(EQ.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 42.2% and a